Sign In
Buy GLUE
$16.52
-6.16 (-27.16%)
At Close: Jul 31, 2026
Monte Rosa Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update
07:00am, Thursday, 09'th May 2024
MRT-2359, a molecular glue degrader (MGD) being developed for MYC-driven solid tumors, advancing in ongoing Phase 1/2 clinical trial; determination of recommended Phase 2 dose expected in Q2 2024; Pha
Monte Rosa Therapeutics Announces the Departure of Owen Wallace, Ph.D., Chief Scientific Officer
04:01pm, Thursday, 02'nd May 2024
BOSTON, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, tod
Recent Price Trend in Monte Rosa Therapeutics (GLUE) is Your Friend, Here's Why
09:51am, Wednesday, 10'th Apr 2024
Monte Rosa Therapeutics (GLUE) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Does Monte Rosa Therapeutics (GLUE) Have the Potential to Rally 107.79% as Wall Street Analysts Expect?
10:56am, Thursday, 04'th Apr 2024
The consensus price target hints at a 107.8% upside potential for Monte Rosa Therapeutics (GLUE). While empirical research shows that this sought-after metric is hardly effective, an upward trend in e
Monte Rosa Therapeutics (GLUE) Is a Great Choice for 'Trend' Investors, Here's Why
09:51am, Friday, 22'nd Mar 2024
Monte Rosa Therapeutics (GLUE) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made
Wall Street Analysts Predict an 117.91% Upside in Monte Rosa Therapeutics (GLUE): Here's What You Should Know
10:56am, Tuesday, 19'th Mar 2024
The mean of analysts' price targets for Monte Rosa Therapeutics (GLUE) points to an 117.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreem
Monte Rosa Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
07:00am, Thursday, 14'th Mar 2024
MRT-2359, a molecular glue degrader (MGD) being developed for MYC-driven solid tumors, advancing in ongoing Phase 1/2 clinical trial; program on track with determination of recommended Phase 2 dose ex
MRT-8102 nominated as first NEK7-directed development candidate, targeting inflammatory diseases driven by IL-1β and the NLRP3 inflammasome MRT-8102 and other NEK7 program MGDs are potentially applic
Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences
07:00am, Wednesday, 31'st Jan 2024
BOSTON, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced
Monte Rosa Therapeutics Provides Corporate Update and Key Anticipated Milestones for 2024
07:15am, Monday, 08'th Jan 2024
Phase 1/2 clinical trial of MRT-2359 in MYC-driven solid tumors on track; recommended Phase 2 dose (RP2D) expected in Q2 2024 Received US FDA Fast Track Designation for MRT-2359 for previously treated
Monte Rosa Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
07:00am, Wednesday, 03'rd Jan 2024
BOSTON, Mass., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, to
Monte Rosa Therapeutics to Present at Piper Sandler Healthcare Conference
07:00am, Tuesday, 21'st Nov 2023
BOSTON, Nov. 21, 2023 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that managemen
Monte Rosa Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate Update
07:00am, Thursday, 09'th Nov 2023
Interim data from Phase 1/2 clinical trial of MRT-2359 demonstrated tumor reductions in patients with biomarker-positive cancers; recommended Phase 2 dose expected in Q2 2024 Announced strategic colla
Monte Rosa Therapeutics Presents Preclinical Data at ACR Convergence 2023 Demonstrating Potential of MRT-6160, a VAV1-targeted Molecular Glue Degrader, to
Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences
07:00am, Friday, 27'th Oct 2023
BOSTON, Oct. 27, 2023 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that managemen
